Biotech firm plans stock sale

Article

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes oncology products, including the pain management product Quadramet and diagnostic radiopharmaceutical Prostascint. The company has exclusive U.S. marketing rights to Combidex, an investigational MR agent designed to aid in the diagnosis of metastatic lymph nodes.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.